A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 12,275 shares of AVXL stock, worth $91,448. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,275
Holding current value
$91,448
% of portfolio
0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$4.11 - $7.04 $50,450 - $86,416
12,275 New
12,275 $69,000
Q3 2023

Oct 24, 2023

SELL
$6.55 - $9.37 $14,180 - $20,286
-2,165 Reduced 6.5%
31,155 $204,000
Q2 2023

Jul 25, 2023

BUY
$7.66 - $9.5 $9,958 - $12,350
1,300 Added 4.06%
33,320 $270,000
Q1 2023

Apr 14, 2023

SELL
$8.32 - $11.75 $382 - $540
-46 Reduced 0.14%
32,020 $274,000
Q4 2022

Feb 08, 2023

BUY
$7.65 - $14.43 $13,739 - $25,916
1,796 Added 5.93%
32,066 $296,000
Q3 2022

Oct 25, 2022

BUY
$8.9 - $12.86 $22,250 - $32,150
2,500 Added 9.0%
30,270 $312,000
Q2 2022

Aug 12, 2022

BUY
$7.31 - $12.84 $14,620 - $25,680
2,000 Added 7.76%
27,770 $278,000
Q1 2022

May 11, 2022

BUY
$9.74 - $17.69 $15,204 - $27,614
1,561 Added 6.45%
25,770 $317,000
Q4 2021

Feb 08, 2022

BUY
$16.88 - $23.31 $16,880 - $23,310
1,000 Added 4.31%
24,209 $420,000
Q3 2021

Nov 02, 2021

SELL
$16.82 - $25.75 $594,788 - $910,571
-35,362 Reduced 60.37%
23,209 $417,000
Q2 2021

Aug 11, 2021

BUY
$10.16 - $28.86 $26,863 - $76,305
2,644 Added 4.73%
58,571 $1.34 Million
Q1 2021

May 14, 2021

SELL
$5.17 - $16.13 $33,568 - $104,732
-6,493 Reduced 10.4%
55,927 $836,000
Q4 2020

Feb 12, 2021

BUY
$4.01 - $7.58 $60,150 - $113,700
15,000 Added 31.63%
62,420 $337,000
Q3 2020

Nov 04, 2020

BUY
$3.8 - $5.0 $41,800 - $55,000
11,000 Added 30.2%
47,420 $216,000
Q2 2020

Jul 17, 2020

SELL
$2.62 - $5.2 $7,414 - $14,716
-2,830 Reduced 7.21%
36,420 $179,000
Q1 2020

Apr 21, 2020

BUY
$2.38 - $5.81 $47,600 - $116,199
20,000 Added 103.9%
39,250 $124,000
Q3 2019

Nov 07, 2019

SELL
$2.22 - $3.9 $3,330 - $5,850
-1,500 Reduced 7.23%
19,250 $61,000
Q2 2019

Aug 06, 2019

BUY
$2.75 - $3.7 $15,125 - $20,350
5,500 Added 36.07%
20,750 $70,000
Q3 2018

Nov 14, 2018

BUY
$2.23 - $3.82 $34,007 - $58,255
15,250 New
15,250 $42,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $581M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.